Exhibit 10.1

 

 

 

U.S. Department of Justice

 

 

 

 

 

Michael J. Sullivan

 

 

United States Attorney

 

 

District of Massachusetts

 

 

 

Main Reception: (617) 748-3100

 

John Joseph Moakley United States Courthouse

 

 

1 Courthouse Way

 

 

Suite 9200

 

 

Boston, Massachusetts 02210

 

 

 

 

January 26, 2009

 

Joseph F. Savage, Jr.

Goodwin Procter, LLP

Exchange Place

Boston, MA, 02109

 

Re: NeuroMetrix, Inc.

 

Dear Mr. Savage:

 

This letter sets forth the agreement ( the “Agreement”) between the United
States Attorney’s Office for the District of Massachusetts (“USAO”) and your
client, NeuroMetrix, Inc. (“NeuroMetrix”):

 

WHEREAS, NeuroMetrix is a Delaware corporation with a principal place of
business in Waltham, Massachusetts, that is in the business of design,
development, promotion, sale, and distribution of a medical device known as the
NC-stat System to physicians nationwide.  The NC-stat System is a medical device
used in physicians’ offices to assist in the diagnosis of neuropathies in
peripheral nerves and the spine that can be caused by or associated with carpal
tunnel syndrome, leg pain, diabetes, and other clinical disorders.

 

WHEREAS, the USAO conducted a criminal investigation regarding certain marketing
referral programs in which NeuroMetrix engaged, to wit, allegations that from in
or about August 2004 through in or about October 2006, NeuroMetrix offered and
paid illegal remuneration to physicians in the form of free boxes of disposable
biosensors to induce them to recommend purchase of the NC-stat System to their
colleagues for the purpose of conducting nerve conduction studies that were
reimbursed in whole or in part by the Medicare Program (the “Subject Matter”). 
As a result of its investigation, the USAO informed NeuroMetrix that the USAO
has determined that there is sufficient basis to seek an indictment of
NeuroMetrix for violations of federal criminal law, specifically for violations
of the Medicare Anti-Kickback Act, 42 U.S.C. § 1320a-7b(b)(2).

 

WHEREAS, NeuroMetrix represents the following:

 

--------------------------------------------------------------------------------

 

(a)                                  NeuroMetrix does not endorse, ratify, or
condone illegal conduct, and has taken steps to prevent such conduct from
occurring in the future;

 

(b)                                 NeuroMetrix discontinued all marketing
referral programs, which programs involved several hundred boxes of free
biosensors which were only a small fraction of the total number of biosensors
purchased by physicians during the relevant time period;

 

(c)                                  NeuroMetrix commenced a thorough internal
investigation under the supervision of a Special Committee of the Board of
Directors immediately upon notice of the allegations of improper conduct;

 

(d)                                 NeuroMetrix cooperated with the USAO in its
investigation, which cooperation included making employees available for
interviews and testimony without subpoena; responding promptly to requests for
documents by producing hundreds of thousands of pages of documents to the USAO,
without subpoena and often within a week to ten days of the request; and
conducting and providing certain analyses on company computer databases for data
requested by the government;

 

(e)                                  NeuroMetrix instituted a voluntary
compliance program under the guidance of outside counsel (“compliance counsel”);

 

(f)                                    NeuroMetrix reformed relevant business
practices based on its internal investigation and review by compliance counsel,
including discontinuance of all marketing referral programs.

 

WHEREAS, NeuroMetrix will enter into a five year corporate compliance agreement
with the Inspector General’s Office of the Department of Health and Human
Services, which requires NeuroMetrix to undertake various compliance obligations
designed to ensure compliance with Federal health care program requirements
(“CIA”).  Among other provisions, the CIA includes “Specific Training”
obligations that require all remaining employees of NeuroMetrix to receive
annual training concerning proper methods for selling, marketing, and promoting
medical devices, including without limitation the antikickback laws and
regulations.  The HHS-OIG monitors compliance with the CIA obligations and
enforces any breaches in accordance with the remedies set forth in the CIA.

 

WHEREAS, the USAO has determined that an indictment of NeuroMetrix may cause
disproportionate harm to innocent individuals including current employees who
did not design or implement the marketing referral programs; NeuroMetrix’s
shareholders and customers who had no involvement in the criminal conduct under
investigation; and patients for whom the NC-stat System provides a point-of-care
alternative for nerve conduction studies; and the USAO does not allege that the
conduct in which NeuroMetrix engaged adversely affected patient health or care.

 

NOW, THEREFORE, the USAO and NeuroMetrix agree as follows:

 

2

--------------------------------------------------------------------------------

 

1.                                       This agreement shall be in effect for
thirty-six (36) months from the date of its execution.

 

2.                                       NeuroMetrix admits to and acknowledges
that it is responsible for the acts of its employees as set forth in the
Information attached hereto as Appendix A, and agrees that the marketing
referral programs violated 42 U.S.C. § 320a-7b(b)(2)(B).  NeuroMetrix agrees
that the facts in Appendix A are accurate in their entirety and NeuroMetrix
agrees not to contradict the facts stated therein.

 

3.                                       NeuroMetrix agrees that, if it violates
any terms of this Agreement, the USAO may file the attached criminal Information
in the United States District Court for the District of Massachusetts charging
NeuroMetrix with a violation of 42 U.S.C. § 1320a-7b(b)(2).

 

4.                                       NeuroMetrix will not, through its
present or future directors, officers, employees, agents, attorneys, affiliates,
parents or subsidiaries, make any public statements, including statements or
positions in litigation in which any United States department or agency is a
party, contradicting any statement of fact set forth in the Information attached
as Appendix A.  Any such contradictory public statement by NeuroMetrix, its
present or future directors, officers, employees, agents, attorneys, affiliates,
parents or subsidiaries shall constitute a breach of this Agreement, and subject
to the provisions in Paragraph 5 below, NeuroMetrix shall be subject to
prosecution on the Information attached to this agreement.

 

5.                                       The decision as to whether any public
statement by any such person contradicting a statement contained in Appendix A
will be imputed to NeuroMetrix for the purpose of determining whether
NeuroMetrix has breached this Agreement shall be at the sole reasonable
discretion of the USAO.  Upon the USAO reaching a determination that such a
contradictory statement has been made by NeuroMetrix, the USAO shall so notify
NeuroMetrix in writing and NeuroMetrix may avoid a breach of this Agreement by
publicly repudiating such statement within five (5) days after written
notification by the USAO.  This paragraph is not intended to apply to any
statement made by any individual in the course of any criminal, regulatory or
civil matter initiated by the USAO against such individual, unless such
individual is speaking on behalf of NeuroMetrix.  Consistent with NeuroMetrix’s
obligation not to make a contradictory public statement, NeuroMetrix may take
good faith positions in litigation involving any private party.

 

6.                                       During the term of this Agreement,
NeuroMetrix agrees to continue to cooperate fully with the USAO, and, as
directed by the USAO, with any other federal, state or foreign law enforcement
or regulatory agency regarding the Subject Matter.  The duty to cooperate
includes an affirmative duty of full and truthful disclosure.  NeuroMetrix shall
truthfully disclose to the USAO all information respecting the activities of
NeuroMetrix and its present and former directors, officers,

 

3

--------------------------------------------------------------------------------

 

employees, agents, attorneys, parents, affiliates and subsidiaries relating to
Subject Matter about which the USAO may inquire, or which NeuroMetrix reasonably
believes is material to the investigation by the USAO.  NeuroMetrix agrees that
its cooperation concerning the Subject Matter shall include, but is not limited
to, the following:

 

(a)                                  providing reasonable access to
NeuroMetrix’s documents, facilities and directors, officers, employees, agents,
affiliates and subsidiaries for matters relating to the investigation of the
Subject Matter;

 

(b)                                 assembling, organizing and producing, or
taking reasonable steps to effectuate the production of, on request from the
USAO, all documents, records, or other tangible evidence related to the
investigation in NeuroMetrix’s possession, custody or control in such reasonable
format that the USAO requests;

 

(c)                                  using its reasonable best efforts to make
available its present or former directors, officers, employees, agents,
affiliates and subsidiaries to provide information and/or testimony related to
the investigation of the Subject Matter as requested, including sworn testimony
before a federal grand jury or in federal trials, as well as interviews with
federal law enforcement authorities.  Cooperation under this sub-paragraph will
include identification of witnesses who, to NeuroMetrix’s knowledge, may have
material information regarding the investigation of the Subject Matter.

 

(d)                                 providing testimony and other information
deemed necessary by the USAO or the court to establish the original location,
authenticity, or other evidentiary foundation to admit into evidence documents
in any criminal case or other proceeding as requested by the USAO; and

 

(e)                                  maintaining NeuroMetrix as a lawfully
organized and adequately capitalized entity for purposes of this Agreement
during the time this Agreement is in effect.

 

Nothing in this paragraph constitutes an agreement that NeuroMetrix will waive
the attorney-client privilege or work product protections.  The cooperation
provisions of this paragraph shall not apply in the event that the USAO pursues
a criminal prosecution against NeuroMetrix.

 

7.                                       In exchange for the agreement of the
USAO set forth in Paragraph 8 below, NeuroMetrix agrees:

 

(a)                                  to accept responsibility as set forth in
Paragraph 2 through 5 above.

 

(b)                                 to pay one million two hundred thousand
dollars ($1,200,000) to the United States Treasury pursuant to electronic fund
transfer instructions

 

4

--------------------------------------------------------------------------------

 

that will be provided by the USAO.  This payment is a material term of this
Agreement.  Failure to make payment within two business days of execution of
this Agreement renders the Agreement null and void.

 

(c)                                  to continue to cooperate with the USAO in
its investigation of the matters described herein as more fully set forth in
Paragraph 6 above.

 

8.                                       In light of NeuroMetrix’s remedial
actions to date and its willingness to (a) acknowledge responsibility for the
behavior of its employees; (b) cooperate with the USAO and other governmental
agencies; (c) demonstrate its future good conduct through full compliance with
the terms of the CIA; and (d) fully comply with all the obligations undertaken
this Agreement, the USAO agrees that it will not prosecute NeuroMetrix on the
attached Information or any other matters investigated by the USAO as of the
date of this Agreement.

 

9.                                       For the term of this Agreement, should
the USAO in its sole reasonable discretion, determine that NeuroMetrix (a) has
knowingly and willfully given false, incomplete or misleading information under
this Agreement; (b) engaged in conduct subsequent to the execution of this
Agreement that constitutes a federal crime; or (c) has otherwise knowingly
breached any provision of this Agreement (these three circumstances, (a),
(b) and (c), are collectively referred to herein as “Breach”), NeuroMetrix
shall, in the USAO’s sole reasonable discretion, thereafter be subject to
prosecution(s) for any federal criminal violations, including, without
limitation, the offense charged in the Information.  NeuroMetrix waives any
right it may have to proceed by way of Indictment for the offense covered by the
attached Information.  NeuroMetrix waives venue and any legal or procedural
defects in the attached Information.  NeuroMetrix agrees that the applicable
statute of limitations period (or any other legal equitable or constitutional
basis for barring prosecution based on the passage of time) for the offense
charged in the Information shall be tolled for a period of time equal to the
term of this Agreement at the time a Breach is declared plus an additional six
months after the declaration of the Breach.  For all other offenses not charged
in the Information that are not time-barred as of the date of this Agreement,
NeuroMetrix agrees that the applicable statute of limitations period (or any
other legal, equitable or constitutional basis upon which a prosecution may be
time-barred), shall be tolled for the time period equal to the term of this
Agreement at the time a Breach is declared plus an additional six months after
the declaration of the Breach.  Further, NeuroMetrix waives any rights it may
have to a speedy trial pursuant to the Fifth or Sixth Amendments to the United
States Constitution, 18 U.S.C. § 3161, Federal Rule of Criminal Procedure 48(b),
any applicable local rule of the United States District Court for the District
of Massachusetts, or any other applicable legal or equitable principle. 
NeuroMetrix’s agreements herein are knowing and voluntary and in express
reliance on the advice of counsel.

 

5

--------------------------------------------------------------------------------

 

10.                                 The decision as to whether conduct and
statements of any individual will be imputed to NeuroMetrix for the purpose of
determining whether NeuroMetrix has committed a Breach shall be in the sole
reasonable discretion of the USAO.

 

11.                                 Should the USAO determine that NeuroMetrix
has committed a Breach, the USAO shall provide written notice to NeuroMetrix of
the alleged breach and provide NeuroMetrix with a two-week period in which to
make a presentation to the USAO to demonstrate that: (a) no Breach has occurred,
(b) the Breach is not a knowing breach, or (c) the Breach has been cured.  The
parties hereto expressly understand and agree that should NeuroMetrix fail to
make a presentation to the USAO within a two-week period, it shall be
conclusively presumed, at the USAO’s option, that NeuroMetrix has committed a
Breach.  In the event of a Breach that results in a prosecution of NeuroMetrix,
such a prosecution may be premised upon any information provided by or on behalf
of NeuroMetrix to the USAO at any time, unless otherwise agreed when the
information was provided.

 

12.                                 NeuroMetrix agrees that in the event that
the USAO, in its sole reasonable discretion, determines that NeuroMetrix has
committed a Breach:  (a) NeuroMetrix will not contest the filing of the
Information nor the admissibility into evidence of the facts set forth in the
Information (paragraphs 1-14)  as binding admissions of NeuroMetrix;
(b) NeuroMetrix will not contradict the contents of the Information; (c) all
statements made by or on behalf of NeuroMetrix and any employee (current or
former), or any testimony given by NeuroMetrix and any employee (current or
former) before a grand jury or elsewhere, and any leads derived from such
statements and testimony, shall be admissible in evidence against NeuroMetrix if
proffered by the USAO in any criminal proceedings brought by the USAO against
NeuroMetrix; (d) NeuroMetrix shall not assert any claim under the U.S.
Constitution, the rules of evidence, common law or any other legal or equitable
principle, that statements made by or on behalf of NeuroMetrix prior to or
subsequent to this Agreement, or any leads therefrom, should be suppressed; and
(e) NeuroMetrix shall not assert that the conduct set forth in the Information
fails to provide a sufficient factual or legal basis to support the charge set
forth in the Information.

 

13.                                 NeuroMetrix agrees that the consequences for
a Breach as set forth in this Agreement, including without limitation, those set
forth in paragraph 3 of this Agreement, are remedies to which the USAO is
entitled in the event of a Breach and shall survive in the event of a Breach. 
NeuroMetrix further agrees that the USAO’s remedies for a Breach are not limited
to those set forth in this Agreement.  NeuroMetrix further agrees that in the
event of a Breach, NeuroMetrix shall nevertheless be bound by its waivers of any
legal, equitable or constitutional rights set forth in this Agreement,
including, without limitation, its waivers in paragraphs 9 and 12 of this
Agreement, and those provisions shall survive even in the event of a Breach.

 

6

--------------------------------------------------------------------------------

 

14.                                 NeuroMetrix agrees that if it sells or
merges all or substantially all of the business operations as they exist as of
the date of this Agreement, it shall include in any contract for sale or merger
a provision binding the purchaser/successor to the obligations described in this
Agreement.

 

15.                                 The parties understand and acknowledge that
this Agreement is binding on NeuroMetrix and the USAO, but specifically does not
bind any other federal agencies, or any state or local law enforcement or
licensing authorities.

 

16.                                 Nothing in this Agreement restricts in any
way the ability of the USAO from proceeding against any individual or entity not
a party to this Agreement.

 

17.                                 This Agreement expires thirty-six (36)
months from the Effective Date; provided that if on the Effective Date the USAO
or any other federal law enforcement or regulatory agency with which the USAO
has directed NeuroMetrix to cooperate is then conducting any investigation,
prosecution or proceeding relating to this investigation, then this Agreement
shall expire on the date that any such investigation, prosecution or proceeding
is finally terminated, as determined by the governmental department or agency
conducting the investigation, prosecution or proceeding.  Between thirty (30)
and sixty (60) calendar days before the expiration of this Agreement,
NeuroMetrix shall submit to the USAO a written certification that NeuroMetrix is
in compliance with this Agreement.

 

18.                                 NeuroMetrix and the USAO agree that this
Agreement, including Appendix A,  shall be made available to the public.

 

19.                                 NeuroMetrix warrants and represents that its
Board of Directors has duly authorized, in a specific resolution, the execution
and delivery of this Agreement by NeuroMetrix, and that the person signing the
Agreement has authority to bind NeuroMetrix.  NeuroMetrix further agrees that it
will deliver concurrently with an executed copy of the Agreement a copy of the
requisite corporate resolution authorizing it to enter into this Agreement.

 

20.                                 This Agreement (including Appendix A)
constitutes the entire agreement, and supersedes all other prior agreements or
understandings, both oral and written, among the parties with respect to the
subject matter hereof.

 

21.                                 This Agreement may not be modified except in
writing signed by the parties.

 

22.                                 This Agreement may be executed in
counterparts, each of which shall be deemed an original but all of which taken
together shall constitute one and the same agreement.  The exchange of copies of
this Agreement and of signature pages by facsimile or electronic transmission
shall constitute effective execution and delivery of this Agreement as to the
parties and may be used in lieu of the original Agreement for all purposes. 
Signatures of the parties transmitted by facsimile or

 

7

--------------------------------------------------------------------------------

 

electronic transmission shall be deemed to be their original signatures for all
purposes.

 

23.                                 NeuroMetrix agrees that should a dispute
between NeuroMetrix and the USAO arise as to the meaning of any provision of
this Agreement, any ambiguities as to the terms of this Agreement shall be
construed in favor of the USAO.

 

24.                                 The Effective Date of this Agreement shall
be the date upon which this Agreement is fully executed by the parties.

 

 

 

 

MICHAEL J. SULLIVAN

 

 

United States Attorney

 

 

 

 

 

/s/ Diane C. Freniere

 

 

Diane C. Freniere

 

 

White Collar Section Chief

 

 

 

 

 

/s/ Susan G. Winkler

 

 

Susan G. Winkler

 

 

Health Care Fraud Chief

 

 

 

NeuroMetrix, Inc.

 

 

 

 

 

By:

/s/ Shai Gozani

 

 

 

Its:

 President & CEO

 

Dated:

2/5/09

 

NeuroMetrix, Inc.

 

 

 

 

 

 

 

 

 

/s/ Joseph F. Savage, Jr.

 

Dated:

2/5/09

 

Joseph F. Savage, Jr.

 

 

 

Goodwin Procter, LLP

 

 

 

Counsel to NeuroMetrix, Inc.

 

 

 

 

8

--------------------------------------------------------------------------------